News | October 28, 2024
Indoco Remedies posts Q2 FY25 consolidated loss at Rs. 9.57 Cr
Indoco Remedies has reported total income of Rs. 434.22 crores during the period ended September 30, 2024
Indoco Remedies has reported total income of Rs. 434.22 crores during the period ended September 30, 2024
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Granules now has a total of 67 ANDA approvals from the USFDA
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
MedGenome reaffirms its commitment to broaden access to quality and affordable genetic solutions for all
He will join in place of Anil Arora, current President- Formulations Operations who will be superannuating in November, 2024
Indoco is comprehensively working on the remedial action plan
Strokes are affecting approximately 1.8 million people annually
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
SIBUR is developing a special grade of polycarbonate compatible with radiation sterilization
Subscribe To Our Newsletter & Stay Updated
